Compare AngloGold Ashanti Limited (AU) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Citius Pharmaceuticals Inc — how do they compare? AngloGold Ashanti Limited trades at $99.96 (market cap $49.19B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: AngloGold Ashanti Limited is far larger — about 2626.3× Citius Pharmaceuticals Inc's market cap, and AngloGold Ashanti Limited pays a 4.65% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AU | CTXR | |
|---|---|---|
Market Cap | $49.19B | $18.73M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $1.82 |
52-Week Low | $52.15 | $0.48 |
Enterprise Value | $48.20B | $14.95M |
Dividend Yield | 4.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
